Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Harbour BioMed in $350 Million Deal for Sichuan Kelun PD-L1 Candidate

publication date: Aug 20, 2018

Harbour BioMed acquired global rights (ex-China) to a PD-L1 candidate from Sichuan Kelun-Biotech in a deal worth up to $350 million. Kelun-Biotech is currently testing A167 (KL-A167) in several China Phase I and II trials among patients with lymphoma and solid tumors. Harbour plans to conduct A167 trials in combination with its own innovative compounds and in collaborations with partners' drugs. Harbour has an R&D site in Shanghai, headquarters in Boston and an antibody discovery operations in Holland. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital